JP2013528213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528213A5 JP2013528213A5 JP2013514169A JP2013514169A JP2013528213A5 JP 2013528213 A5 JP2013528213 A5 JP 2013528213A5 JP 2013514169 A JP2013514169 A JP 2013514169A JP 2013514169 A JP2013514169 A JP 2013514169A JP 2013528213 A5 JP2013528213 A5 JP 2013528213A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- pharmaceutically acceptable
- amount
- weight percent
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000546 pharmaceutical excipient Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 15
- XJDYQYNYISTAMO-GFDYFVENSA-N ethyl (2s)-2-amino-5-[[(2r)-3-benzylsulfanyl-1-[[(1r)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate;hydrochloride Chemical compound Cl.C([C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)C=1C=CC=CC=1)SCC1=CC=CC=C1 XJDYQYNYISTAMO-GFDYFVENSA-N 0.000 claims 10
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 9
- 229960001681 croscarmellose sodium Drugs 0.000 claims 9
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 229960003943 hypromellose Drugs 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 229960001855 mannitol Drugs 0.000 claims 2
- 239000002274 desiccant Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35237710P | 2010-06-07 | 2010-06-07 | |
| US61/352,377 | 2010-06-07 | ||
| PCT/US2011/030376 WO2011156045A2 (en) | 2010-06-07 | 2011-03-29 | Tablet formulation of ezatiostat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013528213A JP2013528213A (ja) | 2013-07-08 |
| JP2013528213A5 true JP2013528213A5 (OSRAM) | 2014-05-15 |
Family
ID=42829329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514169A Withdrawn JP2013528213A (ja) | 2010-06-07 | 2011-03-29 | エザチオスタットの錠剤製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20110300215A1 (OSRAM) |
| EP (1) | EP2576591A2 (OSRAM) |
| JP (1) | JP2013528213A (OSRAM) |
| CN (1) | CN102917694A (OSRAM) |
| AR (1) | AR080895A1 (OSRAM) |
| CA (1) | CA2797458A1 (OSRAM) |
| TW (1) | TW201143761A (OSRAM) |
| WO (1) | WO2011156045A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2704695A1 (en) * | 2011-05-03 | 2014-03-12 | Telik, Inc. | Excipient compatibility with ezatiostat |
| US20130035389A1 (en) | 2011-08-05 | 2013-02-07 | Telik, Inc. | Methods for treating myelodysplastic syndrome with ezatiostat |
| US10156885B2 (en) | 2014-04-07 | 2018-12-18 | Avago Technologies International Sales Pte. Limited | Network energy consumption reduction |
| US11804732B2 (en) | 2015-01-20 | 2023-10-31 | Ge Hybrid Technologies, Llc | Wireless power transmission device, and transmission power control method therefor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599903A (en) | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
| US5114003A (en) * | 1991-03-28 | 1992-05-19 | E. I. Du Pont De Nemours And Company | Tablet vial with desiccant in bottom |
| US5786336A (en) | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
| US5955432A (en) * | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
| US5965164A (en) | 1994-10-28 | 1999-10-12 | Fuisz Technologies Ltd. | Recipient-dosage delivery system |
| CA2328731A1 (en) * | 1998-04-16 | 1999-10-28 | Atsushi Imaizumi | Glutathione derivatives and dosage forms thereof |
| MXPA03009689A (es) * | 2001-04-26 | 2004-02-12 | Bristol Myers Squibb Co | TABLETA FARMACEUTICA QUE TIENE ALTO CONTENIDO DE INGREDIENTE FARMACeUTICO ACTIVO (IFA). |
| US7029695B2 (en) | 2001-07-10 | 2006-04-18 | Telik, Inc. | Therapeutic compositions containing glutathione analogs |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| WO2005065639A2 (en) | 2003-11-21 | 2005-07-21 | Torrent Pharmaceuticals Limited | Novel pharmaceutical compositions |
| CN101133020A (zh) * | 2004-12-03 | 2008-02-27 | 特瓦制药工业有限公司 | 依泽替米贝多晶型 |
| JP4903716B2 (ja) * | 2005-01-06 | 2012-03-28 | テリック，インコーポレイテッド | トリペプチドおよびテトラペプチドチオエーテル |
| ATE460934T1 (de) | 2006-07-19 | 2010-04-15 | Tabuk Pharmaceutical Mfg Co | Pharmazeutische zubereitungen von ciprofloxacin |
| CN101679236B (zh) * | 2007-01-24 | 2013-03-06 | 克尔克公司 | 依泽替米贝的制备方法和其的衍生物 |
| BRPI0807807A2 (pt) | 2007-01-25 | 2014-06-17 | Panacea Biotec Ltd | " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ". |
| EP2187872A4 (en) | 2007-08-13 | 2013-09-18 | Panacea Biotec Ltd | EXTENDED RELEASE COMPOSITIONS COMPRISING SODIUM MYCOPHENOLATE AND METHODS RELATING THERETO |
| AR068745A1 (es) | 2007-10-08 | 2009-12-02 | Panacea Biotec Ltd | Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos |
-
2011
- 2011-03-29 CN CN2011800272195A patent/CN102917694A/zh active Pending
- 2011-03-29 US US13/075,116 patent/US20110300215A1/en not_active Abandoned
- 2011-03-29 EP EP11713930.3A patent/EP2576591A2/en not_active Withdrawn
- 2011-03-29 WO PCT/US2011/030376 patent/WO2011156045A2/en not_active Ceased
- 2011-03-29 JP JP2013514169A patent/JP2013528213A/ja not_active Withdrawn
- 2011-03-29 CA CA2797458A patent/CA2797458A1/en not_active Abandoned
- 2011-04-01 TW TW100111502A patent/TW201143761A/zh unknown
- 2011-04-13 AR ARP110101257A patent/AR080895A1/es unknown
- 2011-09-27 US US13/246,732 patent/US8361971B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010047612A5 (OSRAM) | ||
| JP2014205701A5 (OSRAM) | ||
| FI2508188T3 (fi) | Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita | |
| JP2008501025A5 (OSRAM) | ||
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| NZ599031A (en) | A dosage form containing two or more active pharmaceutical ingredients in different physical forms | |
| TN2009000093A1 (en) | Pharmaceutical compositions comprising nilotinib or its salt | |
| MY153608A (en) | Use of dronedarone for the preparation of medicament for use in the prevention of cardiovascular hospitalization or of mortality | |
| JP2018162255A5 (OSRAM) | ||
| MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
| NZ604055A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
| PE20241581A1 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| HRP20240564T1 (hr) | Novi farmaceutski sastav | |
| CO6440564A2 (es) | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona | |
| MX337603B (es) | Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion. | |
| NZ711179A (en) | Oral formulations of deferasirox | |
| JP2020530832A5 (OSRAM) | ||
| JP2010527347A5 (OSRAM) | ||
| JP2011037832A5 (OSRAM) | ||
| JP2015508082A5 (OSRAM) | ||
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| JP2015511635A5 (OSRAM) | ||
| JP2013544290A5 (OSRAM) |